Evelyn Partners’s AstraZeneca AZN Stock Holding History

Evelyn Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.5B	Buy	+2,237,205	New	+$421M	88.6%	1

Other funds holding AZN

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Prudential plc London, England, United Kingdom $18.4B AUM 23.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Evelyn Partners's AZN Position: Q2 2026 in Review

Evelyn Partners opened a new position in AstraZeneca (AZN) in Q2 2026: 2,237,205 shares worth $41.5B. The stake represents 88.6% of the portfolio and ranks #1 among its holdings.

1,425 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Evelyn Partners held 2,237,205 shares of AstraZeneca worth $41.5B as of Q2 2026.
AstraZeneca was a new Evelyn Partners position in Q2 2026.
AstraZeneca made up 88.6% of Evelyn Partners's portfolio in Q2 2026, its #1 holding.
1,425 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Evelyn Partners's 13F filing for Q2 2026, filed 7 Aug 2026.